ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation With SBS Law - Mykxlg.com

The recent announcement that SBS Law, through the website Mykxlg.com, is soliciting Alnylam Pharmaceuticals, Inc. (ALNY) investors to join a fraud investigation marks more than a potential class-action payday. It signals the kind of high-profile securities matter that routinely captures the attention of federal prosecutors. For officers, directors, and employees of Alnylam, the civil investigation is not an isolated event—it is a tripwire. Where there is smoke in the form of a shareholder fraud claim, the Justice Department often arrives with a flamethrower.

Federal criminal securities enforcement is a deliberate, resource-heavy machine. The statutes are broad, the sentencing stakes are life-altering, and the procedural protections many defendants imagine they possess are far thinner than popular culture suggests. This article explains, from the perspective of a federal criminal defense practice, the legal landscape that unfolds when an investor fraud investigation begins to exist alongside potential criminal exposure. The focus is not on civil liability; it is on what an individual facing a grand jury, an FBI interview, or a target letter needs to know.

The Statutory Framework Governing Criminal Securities Fraud

The cornerstone of any federal securities fraud prosecution is 18 U.S.C. § 1348, enacted as part of the Sarbanes-Oxley Act of 2002. That statute makes it a felony to knowingly execute, or attempt to execute, a scheme or artifice to defraud any person in connection with any security of an issuer with a class of securities registered under Section 12 of the Securities Exchange Act of 1934. The penalty upon conviction is a fine and up to 25 years of imprisonment.

Prosecutors rarely stop with Section 1348. They routinely charge wire fraud under 18 U.S.C. § 1343 and mail fraud under 18 U.S.C. § 1341. Each interstate email, phone call, or electronic press release that furthers an alleged scheme becomes a separate count. Because each execution of the scheme constitutes a distinct offense, a defendant can face dozens—sometimes hundreds—of counts. The statutory maximum for wire and mail fraud is 20 years per count, though the sentences typically run concurrently under the advisory Guidelines.

Equally important is the conspiracy statute, 18 U.S.C. § 1349, which punishes any attempt or conspiracy to commit securities fraud the same as the completed offense. This provision allows the government to charge multiple participants with the same overarching crime without proving that each individual personally executed every component of the scheme. Similarly, 18 U.S.C. § 2, the federal aiding and abetting statute, permits a defendant to be held criminally responsible as a principal for acts committed by others if the defendant willfully associated with the criminal venture and sought to make it succeed.

“The mail, wire, and securities fraud statutes do not criminalize mere mismanagement, bad business judgment, or even a breach of fiduciary duty; they require proof that the defendant acted with specific intent to defraud—that is, knowingly and willfully sought to obtain money or property through false representations or omissions that the defendant knew were materially misleading.”

When a publicly traded pharmaceutical company like Alnylam is suspected of making false or misleading statements about clinical trial results, regulatory prospects, or financial performance, every management-level communication comes under instant scrutiny. The government reviews earnings call transcripts, investor presentations, internal emails, and Slack messages for evidence of conscious misrepresentation. The honest-services theory of fraud, limited after the Supreme Court’s decision in Skilling v. United States, survives when the scheme involves bribes or kickbacks, but common securities fraud cases continue to rest on misappropriation of property or straightforward deception.

How an Investor Investigation Morphs into a Federal Criminal Case

A class-action law firm like SBS Law filing a notice on Mykxlg.com is not itself a criminal event. But it is one of the first dominos. Plaintiffs’ attorneys hire forensic accountants and former SEC litigators who craft detailed complaints that often serve as roadmaps for federal prosecutors. The Department of Justice instructs securities fraud prosecutors to maintain close contact with the SEC’s Division of Enforcement, and there is no wall between the civil and criminal sides when it comes to information sharing—at least until a grand jury is convened.

The investigative trajectory frequently follows this sequence:

• An SEC subpoena for documents arrives. The company and custodians are required to produce vast amounts of records. The SEC’s civil subpoena power is broad, and there is no Fifth Amendment protection for corporate records.
• The SEC staff may decide to refer the matter to the United States Attorney’s Office, or an Assistant U.S. Attorney may open a parallel investigation independently. At that point, the FBI or postal inspectors begin interviewing witnesses.
• A federal grand jury subpoena duces tecum under Rule 17 of the Federal Rules of Criminal Procedure commands the production of documents or tangible items. Unlike an SEC subpoena, a grand jury subpoena is issued in the name of a district court and carries the weight of potential contempt sanctions.
• Agents execute search warrants or use “knock-and-talk” interviews with employees, sometimes catching individuals off guard at their homes at 6:00 a.m. Any statements made during those encounters are admissible if they are voluntary and comply with Miranda—which often does not apply because the individual is not in custody.

Federal grand jury proceedings are secret by law. Rule 6(e) of the Federal Rules of Criminal Procedure prohibits anyone—except government attorneys, the witness, and court personnel—from learning what occurs inside the grand jury room. For a target, this secrecy is disorienting. An employee may not know she is a subject until she receives a target letter, a formal notification that she faces substantial risk of indictment. Target letters usually invite the target to testify before the grand jury, a high-stakes decision that should never be made without a full understanding of the government’s burden and the perils of cross-examination.

One of the most misunderstood protections is the Fifth Amendment right against self-incrimination. Employees often believe that because they are cooperating, they are safe. In reality, the government frequently builds its case by persuading mid-level employees to provide testimony against senior officials. The moment a person becomes a mere witness in the government’s eyes, the dynamic is adversarial—even if the agent’s tone is cordial. Early representation by defense counsel familiar with parallel proceedings is essential to avoid waiving privilege or giving testimony that later becomes the basis for an obstruction charge under 18 U.S.C. § 1519 or false statements under 18 U.S.C. § 1001.

Sentencing Exposure Under the U.S. Sentencing Guidelines

Even seasoned businesspeople underestimate the punishment range for federal securities fraud. The U.S. Sentencing Guidelines are now advisory after United States v. Booker, but every district judge must correctly calculate the Guidelines range and use it as the starting point for a sentence. In fraud cases, the primary driver is U.S.S.G. § 2B1.1, which ties the offense level primarily to the amount of loss.

The loss table in § 2B1.1(b)(1) escalates rapidly. A loss exceeding $550,000 adds 14 offense levels; a loss exceeding $1.5 million adds 16; $3.5 million adds 18; $9.5 million adds 20; and a loss exceeding $25 million adds 22 levels. For a publicly traded biotechnology company with a market capitalization in the billions, an alleged fraud’s claimed loss—often calculated by the government as the decline in stock price attributed to the corrective disclosure multiplied by the number of shares—can easily reach hundreds of millions of dollars. At those numbers, the Guidelines offense level lands in the mid-to-high 30s even before considering enhancements for sophisticated means, abuse of a position of trust, and number of victims.

Sophisticated means, defined in § 2B1.1(b)(10)(C), applies when the scheme involves layers of complexity, such as offshore entities, falsified clinical data, or manipulation of revenue recognition. A public-company executive will almost certainly receive an aggravating-role adjustment under § 3B1.1 if the government alleges that person organized or led the scheme. With an offense level of 35 and a Criminal History Category of I, the advisory range is 168 to 210 months—14 to 17.